Improving treatment outcome assessment in a mouse tuberculosis model.

about

Improving treatment outcome assessment in a mouse tuberculosis model.

Item

http://www.wikidata.org/entity/Q54239058

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

Improving treatment outcome assessment in a mouse tuberculosis model.

@en

Improving treatment outcome assessment in a mouse tuberculosis model.

@nl

type

Item

label

Improving treatment outcome assessment in a mouse tuberculosis model.

@en

Improving treatment outcome assessment in a mouse tuberculosis model.

@nl

prefLabel

Improving treatment outcome assessment in a mouse tuberculosis model.

@en

Improving treatment outcome assessment in a mouse tuberculosis model.

@nl

P1476

Improving treatment outcome assessment in a mouse tuberculosis model.

@en

P2093

Bas C Mourik

http://www.w3.org/2001/XMLSchema#string

Gerjo J de Knegt

http://www.w3.org/2001/XMLSchema#string

Hannelore I Bax

http://www.w3.org/2001/XMLSchema#string

Jurriaan E M de Steenwinkel

http://www.w3.org/2001/XMLSchema#string

Robin J Svensson

http://www.w3.org/2001/XMLSchema#string

Ulrika S H Simonsson

http://www.w3.org/2001/XMLSchema#string

P2860

Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model

A new trial design to accelerate tuberculosis drug development: the Phase IIC Selection Trial with Extended Post-treatment follow-up (STEP)

Comparison of the 'Denver regimen' against acute tuberculosis in the mouse and guinea pig.

Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial

Replacement, reduction and refinement.

Moxifloxacin-containing regimens of reduced duration produce a stable cure in murine tuberculosis.

Clinically significant interactions with drugs used in the treatment of tuberculosis.

PA-824 is as effective as isoniazid against latent tuberculosis infection in C3HeB/FeJ mice

An evaluation of culture results during treatment for tuberculosis as surrogate endpoints for treatment failure and relapse.

Comparative studies evaluating mouse models used for efficacy testing of experimental drugs against Mycobacterium tuberculosis.

P304

5714

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/S41598-018-24067-X

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Annelies Verbon

P577

2018-04-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29632372

http://www.w3.org/2001/XMLSchema#string

P932

5890284

http://www.w3.org/2001/XMLSchema#string